Abstract 292P
Background
Shared decision making (SDM) is a dynamic clinical process where physicians and patients mutually and actively share information and collaborate to discuss available evidence during treatment decisions, and where patients are supported to consider options in order to achieve informed preferences. It has become a hallmark of patient-centered care and communication which highlights physician-patient relationship as the core in improving health outcomes, and refers to the type of care that is responsive to the individual needs and preferences of the patient, ensuring that clinical decisions are aligned with his or her values. In cancer care, preference-sensitive decisions range from screening decisions, to treatment decisions, and to end-of-life care. There is little experience with SDM in the Philippines and its integration into the practice of Oncology. The objective of this study was to explore patient perception and evaluate the extent to which a shared decision-making process is implemented in clinical encounters at the Cancer Institute adult outpatient clinics of the Philippine General Hospital.
Methods
The SDM Q-9 Filipino version was administered to 267 patients who were consulting at the adult outpatient clinics of the Cancer Institute over one month.
Results
More than 90% of the patients surveyed agreed that shared decision-making process were being practiced at the Cancer Institute adult outpatient clinics. Of these, almost half of the respondents answered “somewhat agreed” in all items, except for the domain which sought if the physician helped the patient to understand information which showed stronger trend towards agreement. Notably, the domains involving identification of preferences and shared decision showed weaker trend towards agreement, with 5% and 7% of patients surveyed disagreeing that these steps were being observed in practice, respectively. This indicated that among the nine items of the SDM Q-9, these areas required the most strengthening.
Conclusions
In this study, the investigators observed that cancer patients agreed that shared decision making was being practiced during their clinical encounters with their respective physicians.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session